BACKGROUND: Addition of anti-GD2 antibody ch14.18 to the treatment of neuroblastoma has improved outcomes. The most common side effect of ch14.18 is neuropathic pain, which may in part be complement-mediated. Hu14.18K322A is a humanized anti-GD2 antibody designed to diminish complement activation and induce less pain. We compare the pain outcomes in patients treated with ch14.18 and those treated with hu14.18K322A, and explore dose-dependent relationships between pain scores, opioid requirements, and complement levels in patients treated with hu14.18K322A. PROCEDURE: Opioid (morphine equivalent mg/kg) and anxiolytic requirements during course 1 (4 days) in patients treated with hu14.18K322A and ch14.18 were reviewed. Correlations between antibody dose and pain scores, opioid requirements, and complement levels were examined for patients receiving hu14.18K322A. RESULTS: Patients treated with hu14.18K322A (n = 19) had lower opioid requirements than those who received ch14.18 (n = 9). The differences in median opioid requirements (mg/kg) were statistically significant for the overall course (1.57 vs. 2.41, P = 0.019) as well as for Days 3 (0.34 vs. 0.65, P = 0.005), and 4 (0.32 vs. 0.64, P = 0.010). No difference in anxiolytic use was observed between the two groups. In the group treated with hu14.18K322A, we found a positive correlation between antibody dose administered and pain scores, but no correlation between antibody dose and opioid requirements or changes in complement levels. CONCLUSIONS: In this retrospective analysis, hu14.18K322A induced less pain than ch14.18 based on opioid requirements. Pediatr Blood Cancer 2015;62:224-228.
BACKGROUND: Addition of anti-GD2 antibody ch14.18 to the treatment of neuroblastoma has improved outcomes. The most common side effect of ch14.18 is neuropathic pain, which may in part be complement-mediated. Hu14.18K322A is a humanized anti-GD2 antibody designed to diminish complement activation and induce less pain. We compare the pain outcomes in patients treated with ch14.18 and those treated with hu14.18K322A, and explore dose-dependent relationships between pain scores, opioid requirements, and complement levels in patients treated with hu14.18K322A. PROCEDURE: Opioid (morphine equivalent mg/kg) and anxiolytic requirements during course 1 (4 days) in patients treated with hu14.18K322A and ch14.18 were reviewed. Correlations between antibody dose and pain scores, opioid requirements, and complement levels were examined for patients receiving hu14.18K322A. RESULTS:Patients treated with hu14.18K322A (n = 19) had lower opioid requirements than those who received ch14.18 (n = 9). The differences in median opioid requirements (mg/kg) were statistically significant for the overall course (1.57 vs. 2.41, P = 0.019) as well as for Days 3 (0.34 vs. 0.65, P = 0.005), and 4 (0.32 vs. 0.64, P = 0.010). No difference in anxiolytic use was observed between the two groups. In the group treated with hu14.18K322A, we found a positive correlation between antibody dose administered and pain scores, but no correlation between antibody dose and opioid requirements or changes in complement levels. CONCLUSIONS: In this retrospective analysis, hu14.18K322A induced less pain than ch14.18 based on opioid requirements. Pediatr Blood Cancer 2015;62:224-228.
Authors: R Handgretinger; P Baader; R Dopfer; T Klingebiel; P Reuland; J Treuner; R A Reisfeld; D Niethammer Journal: Cancer Immunol Immunother Date: 1992 Impact factor: 6.968
Authors: Fariba Navid; Paul M Sondel; Raymond Barfield; Barry L Shulkin; Robert A Kaufman; Jim A Allay; Jacek Gan; Paul Hutson; Songwon Seo; Kyungmann Kim; Jacob Goldberg; Jacquelyn A Hank; Catherine A Billups; Jianrong Wu; Wayne L Furman; Lisa M McGregor; Mario Otto; Stephen D Gillies; Rupert Handgretinger; Victor M Santana Journal: J Clin Oncol Date: 2014-04-07 Impact factor: 44.544
Authors: Thorsten Simon; Barbara Hero; Andreas Faldum; Rupert Handgretinger; Martin Schrappe; Dietrich Niethammer; Frank Berthold Journal: J Clin Oncol Date: 2004-09-01 Impact factor: 44.544
Authors: J L Murray; J E Cunningham; H Brewer; K Mujoo; A A Zukiwski; D A Podoloff; L P Kasi; V Bhadkamkar; H A Fritsche; R S Benjamin Journal: J Clin Oncol Date: 1994-01 Impact factor: 44.544
Authors: Susan L Cohn; Andrew D J Pearson; Wendy B London; Tom Monclair; Peter F Ambros; Garrett M Brodeur; Andreas Faldum; Barbara Hero; Tomoko Iehara; David Machin; Veronique Mosseri; Thorsten Simon; Alberto Garaventa; Victoria Castel; Katherine K Matthay Journal: J Clin Oncol Date: 2008-12-01 Impact factor: 44.544
Authors: Aimee C Talleur; Brandon M Triplett; Sara Federico; Ewelina Mamcarz; William Janssen; Jianrong Wu; David Shook; Wing Leung; Wayne L Furman Journal: Biol Blood Marrow Transplant Date: 2017-07-18 Impact factor: 5.742
Authors: Wayne L Furman; Sara M Federico; Mary Beth McCarville; Barry L Shulkin; Andrew M Davidoff; Matthew J Krasin; Natasha Sahr; April Sykes; Jianrong Wu; Rachel C Brennan; Michael William Bishop; Sara Helmig; Elizabeth Stewart; Fariba Navid; Brandon Triplett; Victor M Santana; Armita Bahrami; Gwendolyn Anthony; Alice L Yu; Jacquelyn Hank; Stephen D Gillies; Paul M Sondel; Wing H Leung; Alberto S Pappo Journal: Clin Cancer Res Date: 2019-10-10 Impact factor: 12.531
Authors: Liubov S Kalinichenko; Erich Gulbins; Johannes Kornhuber; Christian P Müller Journal: J Neural Transm (Vienna) Date: 2018-01-10 Impact factor: 3.575
Authors: Brian H Kushner; Irene Y Cheung; Shakeel Modak; Ellen M Basu; Stephen S Roberts; Nai-Kong Cheung Journal: JAMA Oncol Date: 2018-12-01 Impact factor: 31.777
Authors: Sara M Federico; M Beth McCarville; Barry L Shulkin; Paul M Sondel; Jacquelyn A Hank; Paul Hutson; Michael Meagher; Aaron Shafer; Catherine Y Ng; Wing Leung; William E Janssen; Jianrong Wu; Shenghua Mao; Rachel C Brennan; Victor M Santana; Alberto S Pappo; Wayne L Furman Journal: Clin Cancer Res Date: 2017-09-22 Impact factor: 12.531